DIAGNOS Extends Stock Warrant Exercise Period

BROSSARD, Quebec, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 3,502,931 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on June 5, 2024 and set to expire on December 5, 2025.

DIAGNOS Inc. is taking significant steps to enhance its capital structure by extending the exercise period of stock warrants that are set to expire on December 5, 2025. This strategic move is aimed at providing additional flexibility to investors and enhancing liquidity for the company.

The warrants in question, initially issued as part of a financing transaction, allow holders to purchase shares at a predetermined price. By extending the exercise period, DIAGNOS is giving shareholders more time to capitalize on their investments during a period of market volatility and uncertainty. This decision reflects the company's commitment to creating value for its shareholders and supporting their ongoing investment in the company.

In light of the extension, DIAGNOS emphasizes that the decision aligns with its strategic objectives of optimizing its capital resources and fostering investor confidence. The extension allows warrant holders to assess market conditions more thoroughly before making decisions about exercising their warrants, ultimately aiming to create a more favorable economic environment for both the company and its stakeholders.

Furthermore, this action is expected to sustain DIAGNOS’s ongoing projects and initiatives, which are crucial for the company’s growth trajectory. By encouraging the exercise of these warrants, DIAGNOS can tap into additional capital that may be necessary for investing in future opportunities and enhancing its operational capabilities. This proactive approach is indicative of DIAGNOS’s broader strategy to navigate challenges while remaining focused on long-term growth and sustainability.

The extension of the exercise period is also an indication of DIAGNOS’s responsiveness to investor needs. The company recognizes the critical role that its shareholders play in its success and is committed to ensuring that they feel valued and supported throughout their investment journey.

In conclusion, DIAGNOS's decision to extend the exercise period for stock warrants is a strategic maneuver aimed at promoting shareholder value and strengthening investor relationships. This extension not only enhances the flexibility for current warrant holders but also signals the company's commitment to cultivating a robust financial foundation for executing its long-term objectives.